Monoamine metabolite levels in schizophrenia correlate with mismatch negativity

Monoamine metabolite levels in schizophrenia correlate with mismatch negativity - Monoamine metabolite in schizophrenia correlates with MMN

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000035301

Enrollment

Registered

2018-12-19

Start date

2014-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizphrenia

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Japanese patients diagnosed with schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. All participants are right-handed and undergoing medical treatment with antipsychotic drugs.

Exclusion criteria

Exclusion criteria: None reported any neurological disorder, hearing dysfunction, traumatic brain injury, or previous substance abuse or addiction.

Design outcomes

Primary

Measure	Time frame
Correlation between amplitude of mismatch negativity and level of homovanillic acid (HVA) and 5-hydroxyindole acetic acid (5-HIAA) collected from patients' serum.	—

Countries

Japan

Contacts

Public ContactShiga Tetsuya

Fukushima Medical University Department of Neuropsychiatry

tetsuya3@fmu.ac.jp0245471331

Outcome results